Muscular Dystrophy Canada, Canadian Neuromuscular Disease Registry, NMD4C partner to ensure Canadians can access Facioscapulohumeral muscular dystrophy (FSHD) cure(s)
Muscular Dystrophy Canada and the Canadian Neuromuscular Disease Registry are working together with NMD4C to introduce a patient registry and collect information to build a Canada-wide core dataset for Facioscapulohumeral muscular dystrophy.
Learn more about this project at: https://muscle.ca/2023/02/27/mdc-cndr-nmd4c-partner-to-ensure-canadians-can-access-fshd-cures/.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.